Personalized radiation therapy for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a new way to plan radiation treatment for nasopharyngeal cancer, where the target area is tailored to each patient's tumor spread. It aims to improve effectiveness while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have newly diagnosed, non-keratinizing nasopharyngeal cancer (confirmed by biopsy).
- Your cancer has not spread to other parts of the body (stage M0).
- You are able to undergo MRI scans (no claustrophobia or allergy to contrast dye).
- If you are a woman who can become pregnant or a man with a partner who can become pregnant, you agree to use reliable birth control from screening until one year after treatment.
- You have adequate kidney, liver, and blood cell function (tests will be done to confirm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of radiation therapy that adjusts in real-time to treat nasopharyngeal cancer. It is for people who have not received prior radiation and have no distant spread of cancer.
This trial tests whether giving radiation only to the specific lymph nodes that need it works as well as standard radiation for people with nasopharyngeal cancer. It aims to reduce side effects while still controlling the cancer.
This trial is for people with high-risk, newly diagnosed stage T3N1M0 nasopharyngeal cancer. It compares whether you need chemotherapy first (before radiation and chemotherapy together) to improve outcomes.
This trial studies whether lowering the radiation dose to a smaller area around the tumor is safe and effective for people with newly diagnosed nasopharyngeal cancer that has not spread. It may reduce side effects while still curing the cancer.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
Hear when a new Non-metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.